Skip to main content

SYSTEMATIC REVIEW article

Front. Pharmacol.

Sec. Ethnopharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1510657

This article is part of the Research Topic Efficacy and Mechanism of Herbal Medicines and Their Functional Compounds in Preventing and Treating Cardiovascular Diseases and Cardiovascular Disease Risk Factors - Volume II View all 12 articles

Hydroxysafflor yellow A for ischemic heart diseases: A systematic review and meta-analysis of animal experiments

Provisionally accepted
Tianshi Mao Tianshi Mao 1Kaixin Jiang Kaixin Jiang 1Yanting Pang Yanting Pang 1Yi Pan Yi Pan 1Wenhao Jia Wenhao Jia 2Qun Gao Qun Gao 1*Qian Lin Qian Lin 1,3*
  • 1 Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
  • 2 Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, Beijing Municipality, China
  • 3 Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, Beijing, China

The final, formatted version of the article will be published soon.

    Background: Hydroxysafflor yellow A (HSYA) possesses a variety of pharmacological activities which has been demonstrated to be effective against ischemic heart disease (IHD). This study aimed to comprehensively examine the efficacy and summarize the potential mechanisms of HSYA against IHD in animal models.Methods: We conducted electronic searches for preclinical studies on PubMed, Embase, Web of Science, Cochrane Library, CNKI, SinoMed, Wanfang, and Chinese VIP databases from inception to January 31, 2024. The CAMARADES checklist was chosen to assess the quality of evidence. STATA 14.0 software was utilized to analyze the data. The underlying mechanisms were categorized and summarized.Results: Twenty-eight studies involving 686 rodents were included and the mean score of methodology quality was 5.04 (range from 4-7). Meta-analysis observed that HSYA could decrease myocardial infarction size (SMD: –2.82, 95%CI: –3.56 to –2.08, p < 0.001) and reduce the levels of biomarkers of myocardial injury including cTnI (SMD: –3.82, 95%CI: –5.20 to –2.44, p < 0.001) and CK-MB (SMD: –2.74, 95%CI: –3.58 to –1.91, p < 0.001). HSYA displayed an improvement in cardiac function indicators including LVEF, LVSP, +dp/dt max and -dp/dt max. Furthermore, HSYA was able to reduce the levels of MDA, TNF-α and IL-6, while increasing SOD and NO levels. Mechanistically, the protective effect of HSYA in alleviating myocardial injury after ischemia may be associated with NLRP3 inflammasome, Bcl-2, Bax, caspase-3, eNOS proteins, and TLR/NF-κB, Nrf2/HO-1, JAK/STAT, PI3K/Akt, AMPK/mTOR, VEGFA pathways.Conclusions: This study demonstrates that HSYA exerts cardioprotective effects in decreasing infarct size, reducing myocardial enzymes and improving cardiac function, which may be mediated by anti-inflammatory, antioxidant, anti-apoptotic, regulation of autophagy, improvement of microcirculation and promotion of angiogenesis. However, the absence of safety assessment, lack of animal models of co-morbidities, and inconsistency between timing of administration and clinical practice are limitations of preclinical studies.

    Keywords: Hydroxysafflor yellow A, Myocardial Ischemia, Myocardial Infarction, Myocardial ischemia/reperfusion injury, Meta-analysis

    Received: 13 Oct 2024; Accepted: 28 Mar 2025.

    Copyright: © 2025 Mao, Jiang, Pang, Pan, Jia, Gao and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Qun Gao, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
    Qian Lin, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more